Table 1.

 Characteristics of the subjects studied

Subject	NOD2 status	Sex	At time of venesection			Disease classification*
			Age (y)	IBD drugs	Activity	Age at diagnosis (y)	Location	Behaviour
HC1	wt/wt	M	31.8	–
HC2	wt/wt	F	49.1	–
HC3	wt/wt	F	38.4	–
HC4	wt/wt	F	37.3	–
HC5	wt/wt	M	46.0	–
HC6	wt/wt	M	30.3	–
HC7	wt/wt	M	27.9	–
CD1	1007fs/1007fs	F	36.1	Nil	Quiescent	<40	Ileocolon	Penetrating
CD2	1007fs/1007fs	F	77.8	Nil	Quiescent	⩾40	Ileal	Stricturing
CD3	1007fs/1007fs	M	51.3	Nil	Quiescent	<40	Ileal	Stricturing
CD4	1007fs/1007fs	M	27.0	5-ASA, prednisolone	Active	<40	Ileal	Stricturing
CD5	908Arg/1007fs	M	23.0	Nil	Quiescent	<40	Ileal	Penetrating
CD6	908Arg/1007fs	F	36.6	5-ASA	Quiescent	<40	Ileal	Penetrating
CD7	908Arg/1007fs	F	59.3	Nil	Quiescent	<40	Ileal	Stricturing
CD8	908Arg/1007fs	M	55.9	Nil	Quiescent	<40	Ileocolon	Penetrating
CD9	702Trp/1007fs	F	30.9	Nil	Quiescent	<40	Upper GI	Stricturing
CD10	702Trp/1007fs	F	56.3	Prednisolone	Quiescent	<40	Ileocolon	Stricturing
CD11	702Trp/1007fs	F	42.4	Nil	Quiescent	<40	Ileal	Stricturing
CD12	702Trp/1007fs	M	19.2	Azathioprine	Quiescent	<40	Ileocolon	Stricturing
CD13	702Trp/1007fs	F	32.6	Azathioprine	Quiescent	<40	Ileal	Stricturing
CD14	702Trp/1007fs	M	41.1	Nil	Quiescent	<40	Ileal	Stricturing
CD15	702Trp/702Trp	M	46.9	Nil	Quiescent	<40	Ileal	Penetrating
CD16	702Trp/702Trp	F	63.2	Nil	Quiescent	⩾40	Ileal	Stricturing
CD17	702Trp/702Trp	F	48.1	Nil	Quiescent	⩾40	Ileal	Stricturing
CD18	702Trp/702Trp	M	28.2	Azathioprine	Active	<40	Upper GI	Penetrating
CD19	702Trp/702Trp	F	31.3	5-ASA	Quiescent	<40	Ileal	Stricturing

*According to the Vienna classification.³³

NOD2, nucleotide binding oligomerisation domain 2; IBD, inflammatory bowel disease; GI, gastrointestinal.